It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.01% of ...

Teva Pharmaceutical Industries Ltd. ADR 26.47% $18.82B ...

GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...

Deutsche Bank has recently reduced GSK plc (GSK) stock to Hold rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 12, 2024, Jefferies had reduced the stock from a Buy ...

Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for GSK in a research report issued ...

GSK PLC GSK shares inched up 0.04% to £13.34 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.05% to 8,199.11. Supported ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten research firms ...

This often is a signal that the stock you are watching is weak. Waiting for a turn higher may be more intelligent than trying to catch a falling knife. In any case, new support levels are usually ...